Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved... ► Artikel lesen |
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain | BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen |
Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen |
Metavista3D Inc.: Metavista Announces Filing of Annual and Interim Financial Statements and Revocation of MCTO | VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / Metavista3D Inc. (TSXV:DDD)(FSE:E3T) ("Metavista3D" or the "Company") today announced that effective June 23, 2025, the British Columbia Securities... ► Artikel lesen |
Metavista3D Inc.: Metavista Provides Disclosure Clarifications | VANCOUVER, BC / ACCESS Newswire / June 13, 2025 / Metavista3D Inc. (TSXV:DDD)(FSE:E3T) ("Metavista3D" or the "Company") announces that, as a result of a continuous disclosure review by the British Columbia... ► Artikel lesen |
Metavista3D Inc.: Metavista Provides Second Bi-weekly MCTO Status Update | VANCOUVER, BC / ACCESS Newswire / May 30, 2025 / Metavista3D Inc. (TSXV:DDD)(FSE:E3T) ("Metavista3D" or the "Company") is providing this bi-weekly default status report in accordance with National Policy... ► Artikel lesen |
Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen |
Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome | -- Filing marks company's first Marketing Authorization Application in Europe
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization... ► Artikel lesen |
S&P Dow Jones Indices: Acadia Pharmaceuticals Set to Join S&P SmallCap 600 | NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600... ► Artikel lesen |